Point-of-Care Testing in Acute Hemorrhagic and Thrombotic States

Monitoring of the coagulant state in patients who present with acute hemorrhagic or thrombotic conditions can be done by conventional coagulation assays; however, there is increasing attractiveness to the use of point-of-care tests that may yield not only a more rapid result than clinical laboratory testing but may also provide a more complete picture of the condition of the hemostatic system. Most widely used areas of study and application of point-of-care test concern patients who present with massive blood loss (such as in trauma or during major surgery), patients with a hypercoagulable state (such as in sepsis or other systemic inflammatory states), and patients who may need monitoring of antithrombotic treatment for acute coronary syndromes and revascularization procedures.

• References

• 1 Whitten CW, Greilich PE. Thromboelastography: past, present, and future. Anesthesiology 2000; 92 (05) 1223-1225
• 2 Levi M. Self-management of anticoagulation. Expert Rev Cardiovasc Ther 2008; 6 (07) 979-985
• 3 Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34 (08) 709-733
• 4 Stein P, Kaserer A, Spahn GRGH, Spahn DR. Point of care coagulation monitoring in trauma patients. Semin Thromb Hemost 2017; 43 (04) 367-374
• 5 Wirtz MR, Baumann HM, Klinkspoor JH, Goslings JC, Juffermans NP. Viscoelastic testing in trauma. Semin Thromb Hemost 2017; 43 (04) 375-385
• 6 Bolliger D, Tanaka KA. Point-of-care coagulation testing in cardiac surgery. Semin Thromb Hemost 2017; 43 (05) 386-396
• 7 Hill JS, Devenie G, Powell M. Point-of-care testing of coagulation and fibrinolytic status during postpartum haemorrhage: developing a thrombelastography®-guided transfusion algorithm. Anaesth Intensive Care 2012; 40 (06) 1007-1015
• 8 Karlsson O. Experience of point-of-care devices in obstetrical care. Semin Thromb Hemost 2017; 43 (04) 397-406
• 9 Abeysundara L, Mallett SV, Clevenger B. Point-of-care testing in liver disease and liver surgery. Semin Thromb Hemost 2017; 43 (04) 407-415
• 10 Beynon C, Wessels L, Unterberg AW. Point-of-care testing in neurosurgery. Semin Thromb Hemost 2017; 43 (04) 416-422
• 11 Iapichino G, Bianchi P, Ranucci M, Baryshnikova E. Point-of-care coagulation tests monitoring of direct oral anticoagulants and their reversal therapy: state of the art. Semin Thromb Hemost 2017; 43 (04) 423-432
• 12 Johansson PI, Stensballe J, Vindeløv N, Perner A, Espersen K. Hypocoagulability, as evaluated by thrombelastography, at admission to the ICU is associated with increased 30-day mortality. Blood Coagul Fibrinolysis 2010; 21 (02) 168-174
• 13 Park MS, Martini WZ, Dubick MA. , et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma 2009; 67 (02) 266-275 , discussion 275–276
• 14 Collins PW, Macchiavello LI, Lewis SJ. , et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 2006; 135 (02) 220-227
• 15 Wiegele M, Kozek-Langenecker S, Schaden E. Point-of-care testing in burn patients. Semin Thromb Hemost 2017; 43 (04) 433-438
• 16 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86
• 17 Pakala R, Waksman R. Currently available methods for platelet function analysis: advantages and disadvantages. Cardiovasc Revasc Med 2011; 12 (05) 312-322
• 18 Bergmeijer TO, Godschalk TC, Janssen PWA. , et al. How long does it take for clopidogrel and ticagrelor to inhibit platelets in patients undergoing primary PCI? A detailed pharmacodynamic analysis. Semin Thromb Hemost 2017; 43 (04) 439-446